Serum Periostin Levels as a Predictor of Gestational Diabetes Mellitus
Clinical and Experimental Obstetrics & Gynecology · 16.09.2026 · 53 (9)
DOI: 10.31083/ceog53151 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical and Experimental Obstetrics & Gynecology, online erschienen am 16.09.2026. Verfasst von Emine Ahu Koc und 5 weiteren Autor:innen. Die Arbeit nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Diabetes mellitus
Abstract (Originalsprache)
Background
Gestational diabetes mellitus (GDM) is a common pregnancy complication associated with adverse maternal and neonatal outcomes. The identification of novel biomarkers for GDM remains an important clinical objective. The aim of this study was to investigate whether maternal serum periostin levels measured between 24 and 28 weeks of gestation could serve as a biomarker for the diagnosis of GDM and to evaluate their association with maternal and neonatal outcomes.
Methods
This case-control study was conducted at Samsun Training and Research Hospital between January 2024 and February 2025. Serum periostin levels were measured by enzyme-linked immunosorbent assay (ELISA).
Results
Serum periostin levels were significantly higher in the GDM group than in the control group (101.4 (53.6) vs. 34.6 (23.9) ng/mL, p < 0.001). Correlation analysis revealed that serum periostin levels were positively correlated with fasting glucose (r = 0.453, p < 0.001), 1-hour oral glucose tolerance test (OGTT) (r = 0.525, p < 0.001), 2-hour OGTT (r = 0.481, p < 0.001), maternal body mass index (BMI) (r = 0.750, p < 0.001), and fetal birth weight (r = 0.351, p < 0.001). Receiver operating characteristic (ROC) curve analysis demonstrated excellent diagnostic performance for serum periostin (area under the curve [AUC] = 0.932, 95% confidence interval [CI]: 0.899–0.966, p < 0.001). The multivariable model showed even higher diagnostic accuracy (AUC = 0.976, 95% CI: 0.957–0.994, p < 0.001).
Conclusions
Maternal serum periostin levels are significantly associated with the presence of GDM and adverse perinatal outcomes. These findings suggest that periostin may represent a potentially useful biomarker associated with GDM; however, its role in screening or prediction requires further prospective validation.
Zitieren
APA
Koc, E. A., Yılmaz, Z., Celik, S., Aydın, S. M., Arar, M. A., & Gumusburun, N. (2026). Serum Periostin Levels as a Predictor of Gestational Diabetes Mellitus. Clinical and Experimental Obstetrics & Gynecology, 53(9). https://doi.org/10.31083/ceog53151
Vancouver
Koc EA, Yılmaz Z, Celik S, Aydın SM, Arar MA, Gumusburun N. Serum Periostin Levels as a Predictor of Gestational Diabetes Mellitus. Clinical and Experimental Obstetrics & Gynecology. 2026;53(9). doi:10.31083/ceog53151
BibTeX
@article{Koc2026,
author = {Koc, Emine Ahu and Yılmaz, Zehra and Celik, Samettin and Aydın, Sakine Merve and Arar, Mevlude Alpaslan and Gumusburun, Neset},
title = {Serum Periostin Levels as a Predictor of Gestational Diabetes Mellitus},
journal = {Clinical and Experimental Obstetrics & Gynecology},
year = {2026},
volume = {53},
number = {9},
doi = {10.31083/ceog53151}
}
EUVIMED